Neurol. praxi. 2015;16(1):30-32

Patophysiology of motor adverse event of long term treatment of Parkinson’s disease with dopaminergic medication

MUDr. Branislav Veselý1, MUDr. Gabriel Hajaš, PhD.1, doc. MUDr. Miroslav Brozman, CSc.1, prof. MUDr. Ivan Rektor, CSc., FCMA, FANA2
1 Neurologická klinika, Fakultná nemocnica Nitra
2 Masarykova univerzita, Centrum pro abnormní pohyby a parkinsonizmus, 1. neurologická klinika LF MU ve FN u sv. Anny, Středoevropský technologický institut – CEITEC, Brno

Treatment of Parkinson’s disease with dopaminergic preparation has besides the positive effects on the course of the disease many side effects. The most prominent adverse event of long term administration of levodopa and dopamine receptor agonist are motor fluctuation, levodopa induced dyskinesias and psychotic side effects. Authors in the article describe the patophysiology of motor fluctuation and levodopa induced dyskinesias in the patients with Parkinson’s disease treated by dopaminergic medication.

Keywords: dyskinesias, motor fluctuation, priming, pulsative stimulation dopamine denervation, pharmacokinetics of levodopa

Published: January 26, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Veselý B, Hajaš G, Brozman M, Rektor I. Patophysiology of motor adverse event of long term treatment of Parkinson’s disease with dopaminergic medication. Neurol. praxi. 2015;16(1):30-32.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential or new therapies. Nat Rev Neurosci 2001; 2: 577-588. Go to original source...
    2. Bibbiani F, Oh JD, Chase TN. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2000; 57: 1829-1834. Go to original source...
    3. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-931 Go to original source... Go to PubMed...
    4. De la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol 2001; 49: 298-303. Go to original source... Go to PubMed...
    5. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-1389. Go to original source... Go to PubMed...
    6. Fabbrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987; 21: 370-376. Go to original source... Go to PubMed...
    7. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508. Go to original source...
    8. Francesca Del Sorbo, Albanese A. Levodopa-induced dyskinesias and their management, 2008. Journal of Neurology 2008; 255(suppl 4): 32-41,DOI 10.1007/s00415-008-4006-5. Go to original source...
    9. Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D. Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J
    10. Kumar A, Mann S, Sossi V, Ruth TJ, Stoessl AJ, Schulzer M, Lee CS. [11C] DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. Brain 2003; 126: 2648-2655. Go to original source...
    11. Lyons KE, Hubble JP, Troster AI, Pahwa R, Koller WC. Gender differences in Parkinson's disease. Clin Neuropharmacol 1998; 21: 118-121. Go to PubMed...
    12. Metman LV, Konitsiotis S, Chase TN. Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what. Mov Disord 2000; 15: 3-8. Go to original source... Go to PubMed...
    13. Muenter MD, Tyce GM. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects. Mayo Clin Proc 1971; 46: 231-239.
    14. Murata M, Mizusawa H,Yamanouchi H,Kanazawa I. Chronic levodopa therapy enhances dopa absorption: contribution to wearingoff. J Neural Transm 1996, 103: 1177-1185. Go to original source...
    15. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J Neurosci 2000; 20: 7782-7789. Go to original source... Go to PubMed...
    16. Nutt JG, Holford NH. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996; 39: 561-573. Go to original source... Go to PubMed...
    17. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, Rodriguez-Diaz M. The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004; 62: S17-S30. Go to original source...
    18. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M. (2006) Development of dyskinesias in a 5-year trial of ropinirole and Ldopa. Mov Disord 21: 1844-1850. Go to original source... Go to PubMed...
    19. Santini E, Valjent E, Fisone G. Parkinson's disease: levodopa-induced dyskinesia and signal transduction. FEBS J 2008; 275: 1392-1399. Go to original source...
    20. Seiji K. Motor fluctuations in Parkinson's disease, J Neurol 2007; 254(Suppl 5): 32-40 DOI 10.1007/s00415-007-5006-6. Go to original source...
    21. Schneider JS. Levodopa-induced dyskinesias in parkinsonian monkeys: relationship to extent of nigrostriatal damage. Pharmacol Biochem Behav 1989; 34: 193-196. Go to original source...
    22. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000; 123: 2297-2305. Go to original source...
    23. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 25: 631-634. Go to original source...
    24. Wagner CA, Lang F, Broer S. Function and structure of heterodimeric amino acid transporters. AM J Physiol Cell Physiol 2001; 281: C1077-C1093. Go to original source... Go to PubMed...
    25. Zappia M, Oliveri RL, Montesanti R, Rizzo M, Bosco D, Plastino M, Crescibene L, Bastone L, Aguglia U, Gambardella A, Quattrone A. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 1999; 52: 763-767. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.